Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Product Liability Suits: Testosterone, Lipitor Grow While Yaz, Pradaxa Settle

Executive Summary

2014 saw some big settlements in personal injury suits involving Rx drugs, but it’s unclear whether this is a trend or just situation-specific decision-making, since fierce litigation continues for many other products.

You may also be interested in...



US FTC Calls Out Personal Injury Rx Ads As Potentially Misleading

The US Federal Trade Commission says the ads may be causing patients to stop taking medications, asks that they include scientifically sound information and be careful using scare tactics.

US FDA Should Regulate Ads Soliciting Mass Tort Suits, Group Says

Citing deaths and injuries caused when people stopped talking Xarelto in response to advertisements, US Chamber Institute for Legal Reform recommends Congress give FDA authority to halt misleading lawsuit ads.

Product Liability Litigation Playbook: Pros And Cons For Pharma

Drug makers are winning cases by getting expert testimony tossed, but the AndroGel verdict shows how narrow claims can benefit plaintiffs. The Pink Sheet offers a look at drugs in multidistrict litigation from Abilify to Zoloft.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS056600

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel